Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 Mar;68(2):94–106. doi: 10.1016/j.curtheres.2007.04.002

Anti-albuminuric effect of losartan versus amlodipine in hypertensive Japanese patients with type 2 diabetes mellitus: A prospective, open-label, randomized, comparative study

Yasuhiro Ohno 1,1, Akiyoshi Nishimura 1, Hiroshi Iwai 1, Noriyuki Hirota 1, Takaaki Yamauchi 1, Mika Fujimoto 1, Toshiyuki Miyatake 1, Hiroshi Arai 1, Norihiko Aoki 1
PMCID: PMC3966014  PMID: 24678123

Abstract

Abstract

Background

The antiproteinuric effect of the angiotensin II receptor-antagonist losartan has been observed in patients with type 2 diabetes mellitus (T2DM). Proteinuria is considered to be a predictor of the progression of kidney disease.

Objective

The aims of the present study were to compare and examine the ability of losartan and amlodipine to ameliorate albuminuria in hypertensive Japanese patients (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) with T2DM and whether the change in albuminuria was associated with a change in glomerular filtration rate (GFR).

Methods

This prospective, open-label, randomized, comparative study was conducted over 3 months at the Kinki University School of Medicine, Osaka-Sayama, Japan. Hypertensive patients with T2DM were enrolled and randomly assigned to 1 of 2 study groups receiving either losartan (25–100 mg/d) or the calcium channel-blocker amlodipine (2.5–5 mg/d). Urinary albumin excretion (UAE), creatinine clearance, and GFR were recorded at study initiation (baseline) and study end (month 3). The GFR was measured from the fractional renal accumulation of 99mTc-diethylenetriaminepentaacetic acid. Adverse events (AEs) were monitored by a clinical research nurse during the examination.

Results

Fifty patients were asked to enroll and 38 returned the informed written consent. Thirty-five Japanese patients were included in the final study analysis. Seventeen patients were assigned to the losartan group (male sex, 10 [58.8%]; mean [SD] age, 58.1 [8.2] years) and 18 were assigned to the amlodipine group (male sex, 10 [55.6%]; mean [SD] age, 57.4 [8.9] years); no significant between-group difference in demographics was observed. A significant decrease from baseline to month 3 of mean (SD) UAE was observed in the losartan group (352.5 [556.6] mg/d vs 275.7 [466.1] mg/d; P = 0.048). No significant difference in mean (SD) UAE was observed in the amlodipine group for the same time period (298.2 [416.6] mg/d vs 322.7 [415.4] mg/d). There was a statistically significant difference found in the mean (SD) percent change of UAE from baseline to month 3 in the losartan group compared with the amlodipine group (−23.52 [28.42] vs +27.90 [63.51]; P = 0.004). Neither group was associated with a significant change in GFR during the course of the study. No patient discontinued the study due to AEs that were considered, by the investigator, to be possibly or probably associated with study treatment.

Conclusions

Treatment with losartan, but not amlodipine, was associated with a reduction in albuminuria in these hypertensive Japanese patients with T2DM within a period as short as 3 months. Neither drug was associated with a significant change in GFR. Therefore, the reduction of UAE was independent of a change in the GFR.

Key Words: albuminuria, hypertension, glomerular filtration rate, losartan, amlodipine

Full Text

The Full Text of this article is available as a PDF (199.8 KB).

References

  • 1.Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803–1817. doi: 10.1046/j.1523-1755.2000.00031.x. [DOI] [PubMed] [Google Scholar]
  • 2.Hostetter TH, Rosenberg ME. Renal hemodynamics and permselectivity. J Am Soc Nephrol. 1990;1:S55–S58. [PubMed] [Google Scholar]
  • 3.Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet. 1988;2:530–533. doi: 10.1016/s0140-6736(88)92657-8. [DOI] [PubMed] [Google Scholar]
  • 4.Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300:297–300. doi: 10.1136/bmj.300.6720.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Haffner SM, Stern MP, Gruber MK. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis. 1990;10:727–731. doi: 10.1161/01.atv.10.5.727. [DOI] [PubMed] [Google Scholar]
  • 6.Weir M, Dzau VJ. The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens. 1999;12:205S–213S. doi: 10.1016/s0895-7061(99)00103-x. [DOI] [PubMed] [Google Scholar]
  • 7.Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462. doi: 10.1056/NEJM199311113292004. for the Collaborative Study Group. [DOI] [PubMed] [Google Scholar]
  • 8.Maschio G, Alberti D, Janin G. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945. doi: 10.1056/NEJM199604113341502. for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. [DOI] [PubMed] [Google Scholar]
  • 9.Giatras I, Lau J, Levey AS. Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med. 1997;127:337–345. doi: 10.7326/0003-4819-127-5-199709010-00001. for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Disease Study Group. [DOI] [PubMed] [Google Scholar]
  • 10.Miller TR, Anderson RJ, Linas SL. Urinary diagnostic indices in acute renal failure: A prospective study. Ann Intern Med. 1978;89:47–50. doi: 10.7326/0003-4819-89-1-47. [DOI] [PubMed] [Google Scholar]
  • 11.Gates GF. Glomerular filtration rate: Estimation from fractional renal accumulation of 99mTc-DTPA (Stannous) AJR Am J Roentgenol. 1982;138:565–570. doi: 10.2214/ajr.138.3.565. [DOI] [PubMed] [Google Scholar]
  • 12.Fernández-Andrade C, Russo D, Iversen B. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl. 1998;68:S120–S124. doi: 10.1038/sj.ki.4490576. [DOI] [PubMed] [Google Scholar]
  • 13.Brenner BM, Cooper ME, de Zeeuw D. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. doi: 10.1056/NEJMoa011161. for the RENAAL Study Investigators. [DOI] [PubMed] [Google Scholar]
  • 14.Iino Y, Hayashi M, Kawamura T. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: A report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) study. Clin Exp Nephrol. 2003;7:221–230. doi: 10.1007/s10157-003-0241-3. for the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. [DOI] [PubMed] [Google Scholar]
  • 15.Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol. 1998;9:2096–2101. doi: 10.1681/ASN.V9112096. for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) [DOI] [PubMed] [Google Scholar]
  • 16.Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106:672–678. doi: 10.1161/01.cir.0000024416.33113.0a. for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. [DOI] [PubMed] [Google Scholar]
  • 17.Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 1990;38:167–184. doi: 10.1038/ki.1990.182. [DOI] [PubMed] [Google Scholar]
  • 18.Parving HH, Lehnert H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878. doi: 10.1056/NEJMoa011489. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. [DOI] [PubMed] [Google Scholar]
  • 19.Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens. 1999;12:195S–203S. doi: 10.1016/s0895-7061(99)00104-1. [DOI] [PubMed] [Google Scholar]
  • 20.Gansevoort RT, De Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861–867. doi: 10.1038/ki.1994.113. [DOI] [PubMed] [Google Scholar]
  • 21.Andersen S, Tarnow L, Rossing P. Renoprotective effects of angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601–606. doi: 10.1046/j.1523-1755.2000.00880.x. [DOI] [PubMed] [Google Scholar]
  • 22.Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest. 1976;36:35–43. doi: 10.1080/00365517609068016. [DOI] [PubMed] [Google Scholar]
  • 23.Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest. 1972;30:271–274. doi: 10.3109/00365517209084290. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES